The Food and Drug Administration has approved special handling instructions to allow health care providers to use certain opioid and other intravenous drug products made by Hospira that were on hold due to low potential for a manufacturing defect but are in short supply. Health care providers should not use the Carpuject Luer Lock Glass Syringe products if the cartridges are visibly damaged or contain particulate matter, according to the instructions. Hospitals and health systems continue to experience critical shortages of a number of injectable opioid medications. Commenting this month on a Drug Enforcement Administration proposed rule on controlled substances quotas, AHA urged the agency to include drug shortages as a factor when setting and adjusting aggregate and individual manufacturers’ production quotas for controlled substances, and joined with the American Society of Health-System Pharmacists and others in requesting similar changes to the proposed rule.

Related News Articles

Headline
The Food and Drug Administration yesterday released revised draft guidance for facilities that compound human drugs as outsourcing facilities.
Headline
The Food and Drug Administration yesterday approved a mobile medical application to help increase retention in outpatient treatment programs for opioid use…
Headline
U.S. life expectancy at birth continued to decline in 2017, from 78.7 years to 78.6, largely due to increase deaths from unintentional injuries, according to a…
Insights and Analysis
Parkview Health is working to develop a mobile app that would serve as an intervention for Indianans struggling with opioid-related substance use disorders.…
Insights and Analysis
Also in this weekly roundup of health care news: the county that’s leading the nation in reversing opioid overdose deaths, and meth-related overdoses are on…
Weekly Reading
Also in this weekly roundup of health care news: the county that’s leading the nation in reversing opioid overdose deaths, and meth-related overdoses are on…